<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073692</url>
  </required_header>
  <id_info>
    <org_study_id>739857</org_study_id>
    <nct_id>NCT05073692</nct_id>
  </id_info>
  <brief_title>Comparison of Type 2 Diabetes Pharmacotherapy Regimens</brief_title>
  <acronym>ON TARGET DM</acronym>
  <official_title>Comparison of Type 2 Diabetes Pharmacotherapy Regimens Using Targeted Learning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaiser Permanente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Geisinger Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henry Ford Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaiser Permanente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to help patients with type 2 diabetes and their clinicians: (a)&#xD;
      identify which glucose lowering medications have the most favorable effects on heart health&#xD;
      and other patient-important outcomes, (b) inform the timing of medication initiation, and (c)&#xD;
      identify whether medication benefits apply equally to all adults with type 2 diabetes, or may&#xD;
      be different based on age, sex, race/ethnicity, baseline heart health status, baseline renal&#xD;
      function, or other factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will conduct head-to-head comparisons of type 2 diabetes mellitus (T2DM) treatment&#xD;
      strategies using observational data from real-world clinical settings to assess&#xD;
      cardiovascular disease (CVD) outcomes and other patient-centered outcomes in T2DM patients&#xD;
      with moderate baseline CVD risk who are treated with each of these four classes of&#xD;
      glucose-lowering medications known as SGLT2, GLP-1RA, DPP4, and SU. To mitigate bias concerns&#xD;
      related to confounding and informative loss to follow-up, analyses will be based on modern&#xD;
      causal inference methods combined with machine learning that emulate intention-to-treat (ITT)&#xD;
      and per-protocol (PP) analyses of pragmatic randomized trials with active comparators to&#xD;
      provide the most robust and precise estimates of relative and absolute effects we would&#xD;
      expect in usual care settings.&#xD;
&#xD;
      Specific Aims and Hypotheses:&#xD;
&#xD;
      Aim 1. Compare the effect off SGLT21, GLP-1RA, DPP4, and SU on each study outcome in adults&#xD;
      with T2DM when each type of medication is (a) initiated as second-line therapy after&#xD;
      metformin, and (b) initiated as first-, second-, or third-line therapy, or after any history&#xD;
      of glucose-lowering therapy independent of prior metformin use.&#xD;
&#xD;
      Aim 2. Compare the effect on each study outcome of earlier versus later initiation of SGLT2i,&#xD;
      GLP-1RA, DPP4, SU as first-, or second-, or third-line therapy, or after any history of&#xD;
      glucose-lowering therapy triggered by various changes in A1C, or CVD risk, or other patient&#xD;
      characteristics.&#xD;
&#xD;
      Aim 3. Assess in each of the prior analyses whether the treatment effects on study outcomes&#xD;
      vary across categories of baseline CVD risk and CVD event history, renal function, congestive&#xD;
      heart failure status, age, sex and race/ethnicity, or other patient characteristics.&#xD;
&#xD;
      Glucose-lowering medications will be compared at both the class and agent level. The key&#xD;
      outcomes that will be considered are MACE 3-point, Myocardial Infarction, Stroke, Heart&#xD;
      Failure, Hospitalization, Coronary or Carotid Artery Stent or Bypass Procedure, CVD&#xD;
      Mortality, Overall Mortality. Additional patient-centered outcomes will be specified based on&#xD;
      insights from stakeholder members of the research team.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of 3-point Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>1/1/2014 to 6/30/2021</time_frame>
    <description>3-point MACE is defined as a single outcome measure, which is a composite measure of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular disease death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">270000</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Cardiovascular Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU</intervention_name>
    <description>Exposure to the class of drugs known as Sulfonylureas (SU)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP4</intervention_name>
    <description>Exposure to the class of drugs known as Dipeptidyl peptidase-4 inhibitors (DPP4)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2i</intervention_name>
    <description>Exposure to the class of drugs known as Sodium-glucose cotransporter-2 inhibitors (SGLT2i)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLP-1RA</intervention_name>
    <description>Exposure to the class of drugs known as Glucagon-like peptide-1 receptor agonists (GLP-1RA)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2i or GLP-1RA</intervention_name>
    <description>Exposure to either SGLT2i or GLP-1RA</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin (DPP4)</intervention_name>
    <description>Exposure to agent Linagliptin (DPP4)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide (GLP-1RA)</intervention_name>
    <description>Exposure to agent Exenatide (GLP1-RA)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide (GLP-1RA)</intervention_name>
    <description>Exposure to agent Liraglutide (GLP-1RA)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin (SGLT2i)</intervention_name>
    <description>Exposure to agent Empagliflozin (SGLT2i)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride (SU)</intervention_name>
    <description>Exposure to agent Glimepiride (SU)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide (SU)</intervention_name>
    <description>Exposure to Glimepiride (SU)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride (SU) or Glipizide (SU)</intervention_name>
    <description>Exposure to agent Glimepiride (SU) or Glipizide (SU)</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU or DPP4 (excluding saxagliptin and alogliptin)</intervention_name>
    <description>Exposure to either SU or DPP4 excluding Saxagliptin and Alogliptin</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)</intervention_name>
    <description>Exposure to either Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients from six large care delivery systems with integrated administrative and EHR&#xD;
        clinical data sources (Geisinger in Pennsylvania, Henry Ford Health System in Michigan,&#xD;
        HealthPartners Institute in Minnesota and Wisconsin, and Kaiser Permanente of Northern&#xD;
        California, Southern California, and Hawaii) who were new users of glucose-lowering&#xD;
        medications between 01/01/2014 and 06/30/2023.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Dispensing of either of the set of drugs being compared&#xD;
&#xD;
          -  No prior dispensing of any of the drugs compared&#xD;
&#xD;
          -  Evidence of Type 2 Diabetes Mellitus diagnosis&#xD;
&#xD;
          -  Age 18-85&#xD;
&#xD;
          -  Not currently pregnant&#xD;
&#xD;
          -  No evidence of dementia or short-term life expectancy from prior cancer diagnoses&#xD;
&#xD;
          -  History of ≥2 years of continuous health plan membership&#xD;
&#xD;
          -  ≥1 A1c test in the past 18 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Romain S. Neugebauer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaiser Permanente</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick J O'Connor, MD, MA, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>HealthPartners Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Romain S. Neugebauer, PhD</last_name>
    <phone>510-891-3234</phone>
    <email>Romain.S.Neugebauer@kp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rosa M. Hippler, MA</last_name>
    <phone>5108913721</phone>
    <email>Rosa.M.Hippler@kp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Romain S. Neugebauer</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain S Neugebauer, PhD</last_name>
      <phone>510-891-3234</phone>
      <email>Romain.S.Neugebauer@kp.org</email>
    </contact>
    <contact_backup>
      <last_name>Rosa M Hippler</last_name>
      <phone>510-891-3721</phone>
      <email>Rosa.M.Hippler@kp.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Southern California</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaejin An, PhD</last_name>
      <phone>626-807-4298</phone>
      <email>Jaejin.X.An@kp.org</email>
    </contact>
    <contact_backup>
      <last_name>Cecilia Portugal</last_name>
      <phone>626-710-6777</phone>
      <email>Cecilia.X.Portugal@kp.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caryn Oshiro, PhD</last_name>
      <phone>808-432-5555</phone>
      <phone_ext>1486</phone_ext>
      <email>Caryn.ES.Oshiro@kp.org</email>
    </contact>
    <contact_backup>
      <last_name>Yannica Martinez</last_name>
      <phone>808-432-5555</phone>
      <phone_ext>1571</phone_ext>
      <email>Yannica-theda.s.martinez@kp.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cassidy-Bushrow, PhD</last_name>
      <phone>313-874-6097</phone>
      <email>acassid1@hfhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa King</last_name>
      <phone>313-874-6223</phone>
      <email>Lking2@hfhs.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>HealthPartners Institute</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick O'Connor, MD, MA, MPH</last_name>
      <phone>952-967-5080</phone>
      <email>patrick.j.oconnor@healthpartners.com</email>
    </contact>
    <contact_backup>
      <last_name>Kris Ohnsorg, RN, MPH, PMP</last_name>
      <email>Kris.A.Ohnsorg@HealthPartners.Com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Geisinger</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17821</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jove Graham, PhD</last_name>
      <phone>570-214-9578</phone>
      <email>jhgraham1@geisinger.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vanessa Duboski</last_name>
      <phone>570-714-6682</phone>
      <email>vduboski1@geisinger.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 14, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 11, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Medication</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Saxagliptin</mesh_term>
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Glipizide</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

